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IN order to find an explanation for corticosteroid
resistance we assessed whether inhibition by
dexamethasone (DEX) of the stimulated produc-
tion of TNF-0c, IL-6, PGE2 and LTB4 by peripheral
blood mononuclear cells (MNC) depends on
binding to the glucocorticoid receptor (GR), and
whether it is determined by the number or the
affinity of the GR of these cells. GR number and
affinity of MNC were determined by means of a
whole cell DEX binding assay. MNC were incu-
bated with DEX and LPS or A23187 in the absence
or presence of RU486, a potent steroid antagonist.
DEX caused a concentration dependent inhibition
of TNF-0c, IL-6 and PGE2 production but had no
effect on LTB4 production. RU486 significantly
blocked the effect of DEX, but no correlations
were found between the inhibition of mediator
release and the Kd or receptor number.
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Introduction
Corticosteroids decrease the severity of inflam-
mation and cause a subjective improvement in
the majority, but not in all, patients with non-
infectious inflammatory disorders such as inflam-
matory bowel disease (IBD), asthma
2 and rheu-
matoid arthritis.3 The anti-inflammatory effects of
corticosteroids are ascribed to inhibition of the
production of mediators of inflammation, includ-
ing eicosanoids and cytokines.
4-6
Several control studies have shown that topical
or systemic corticosteroids are much more effec-
tive than placebo controls, but that not all
patients improve. Depending on the dose and
route of application, duration of the treatment,
severity of the exacerbation and the parameters
under investigation, approximately 10-40% of
patients do not respond or respond insufficiently
to corticosteroids.7’8
Stimulation of mononuclear cells (MNC) by
lipopolysaccharide (LPS) or Ca-ionophore
enhances the production of a range of inflamma-
tory mediators by these cells such as the cyto-
kines tumour necrosis factor-0 (TNF-z) and
interleukin 6 (IL-6), and the eicosanoids prosta-
glandin E2 (POt2) and leukotriene B4 (LTB4).9
This provides an in vitro model for studying the
anti-inflammatory properties of corticosteroids.
In order to clarify some aspects of the
mechanism through which corticosteroids exert
their anti-inflammatory effects we examined the
effect of dexamethasone (DEX) on the produc-
tion of mediators of inflammation by human
MNC in vitro and assessed whether this effect
depends on binding of corticosteroids to the glu-
cocorticoid receptor (GR).
The hypothesis of this study was that the inhi-
bition of the production of mediators of inflam-
mation by corticosteroids is a glucocorticoid
receptor-mediated process. We furthermore
tested whether the ability of DEX to inhibit the
LPS-stimulated production of TNF-z, IL-6, PGE2
and the Ca
2 +-ionophore enhanced LTB4 produc-
tion by MNC is determined by the number or
affinity of glucocorticoid receptors (GR) on these
cells.
Materials and Methods
Healthy volunteers.. Approval for this study was
obtained from the Medical Ethics Committee of
the University Hospital Rotterdam. Venous blood
was obtained from nine healthy adults, ranging in
age from 22 to 37 years, who joined voluntarily
after full explanation of the nature, significance
and scope of the study. None of the subjects had
taken corticosteroids or any other anti-inflamma-
tory drug for a period of at least 4 weeks prior
to donating blood.
Isolation of human MNC. Mononuclear cells
were isolated from the heparinized venous
blood immediately after blood sampling. The
method used was a modification of the techni-
que originally described by Boyum.
1 Briefly, the
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blood was diluted 1.1 with phosphate buffered Statistics.. The effect of DEX on the stimulated
saline (PBS; Oxoid, UK) before fractionating it release of each mediator was studied in nine
by a one-step Ficoll-Paque gradient (Pharmacia, separate experiments, with blood from nine
Sweden) centrifugation at 1100 x g for 15 min different donors. Values are expressed as mean
at 20C. The interphase was washed in PBS and _
S.E.M. Control and DEX-treated cell cultures
resuspended in Dulbecco’s Modified Eagle’s were compared by paired t-test. /values <
Medium (DMEM) containing HEPES and foetal 0.05 were considered significant. The effect of
calf serum (Gibco, UK), supplemented with DEX alone versus the effect of DEX after pre-
penicillin and streptomycin (Flow Lab, UK). incubation with RU486 was compared by
Cells were stained by Hemacolor (Merck, Manova.
Germany), the final yield of MNC was greater
than 95% and the cell viability (tested by Trypan
blue exclusion) was over 97%.
Culturing ofMNC and measurementJcytokines Mediator production by MNC: After the incuba-
and eicosanoida: The cells (2 x 10 per well) tion period LPS-stimulated MNC released the
were cultured in DMEM and incubated in the mediators measured in the following concentra-
presence or absence of varying concentrations of tions: TNF-a, 90 ___
25 pg/10 cells; IL-6, 1165 +
DEX (Genfarma, The Netherlands) for 24h prior 320 pg/106 cells; PGE2, 1420 340 pg/10.
to stimulation with LPS (5 l.tg/ml, E. coli 0111:B4, MNC stimulated with Ca2+-ionophore released
Sigma, USA) for 24 h or Ca
2 +-ionophore 2970 ___
940 pg LTB4/10 cells.
(A23187, 1 l.tM, Sigma, USA) for 15 min. All incu-
bations were performed at 37C in a humidified Effect ofDEX on mediator release by MNC: The
atmosphere of 5% CO2 and 95% air. DEX was inhibitory effect of DEX on TNF-a production
dissolved in culture medium, and the concentra- was of comparable magnitude to that of IL-6
tion of DEX varied from 10-9 to 10-5M. and PGE2, with an IC50 value (concentration of
TNF-a and IL-6 were measured by commer- DEX that causes a 50% decrease in mediator
cially available ELISA kits (Central Laboratory for release) of 65nM in comparison to 145 and
Blood Transfusion, The Netherlands), whereas 140nM for IL-6 and PGE2 respectively. There
PGE2 and LTB4 were determined by specific was a considerable inter-individual variation in
radioimmunoassays (standards, Sigma, USA; H- IC50 values in response to DEX with a 95%
labels, Amersham, UK; and antibodies, Advanced confident interval of 10-400nM for TNF-a, 15-
Magnetics Inc., USA). 1095 nM for IL-6 and 30-690nM for PGE2. The
The effects of different concentrations of DEX effects of DEX on the production of the studied
on secretion of TNF-a, IL-6 and PGE2 were mediators are shown in Fig. 1. DEX had no
expressed as percentage inhibition of production effect on Ca
2 + ionophore-stimulated LTB4
in control cultures (cells incubated with DMEM release.
plus supplements and LPS).
Antagonism of the effects of DEX in MNC by
Assessment ofglucocorticoid receptor number by RU486: Incubation of MNC with RU486, a steroid
a whole cell assay.. The method used was that receptor antagonist, for 2 h prior to the addition
described by Lamberts et al.,
11 but a 1000-fold of DEX diminished the inhibitory effect of the
excess of unlabelled RU486 (Roussel, France), a glucocorticoid in a dose dependent manner
corticoid receptor antagonist, was used instead of (Fig. 2).
an excess of unlabelled DEX. A stock solution
was made by dissolving RU486 in ethanol. This Assessment of glucocorticoid receptor number
solution was diluted in culture medium. The final and Kd in MNC. Glucocorticoid receptor
concentration of ethanol in the assay samples content was 4430 +_ 340 sites/cell (mean ___
was less than 0.1%. S.E.M.) and the I 9.5 ___
0.7nM. In Fig. 3 a
In order to enhance the dissociation of endo- representative Scatchard p_lot from one experi-
genously bound corticoids, the MNC used in the ment of the binding of H-DEX to glucocorti-
assay were washed three times in DMEM, each cold receptors of MNC is shown. The slope is
time allowing for an equilibration period of equal to the negative reciprocal of the dissocia-
12 30min at 37C in a shaking waterbath, tion constant (-1/K), and the intercept on the
Specific binding was determined by subtract- abscissa equal to the total concentration of
ing the amount of nonspecifically bound radio- receptors (Bmax). NO correlations were found
ligand from the total amount bound. Data were between the inhibition of mediator release and
analysed by constructing a Scatchard plot.1 I or receptor number.
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FIG. 1. Effect of DEX on the secretion of (A) TNF- (O) and IL-
6(V); and (B) PGE2 (O) and LTB4 (I-I) by MNC cultures stimu-
lated by LPS (5 lg/ml). Production is presented as a percentage,
2+ mean -t- S.E.M. (vertical bars), of LPS-or Ca -ionophore
enhanced release and represents nine experiments performed
on MNC from nine different donors. *Significance with p < 0.05
compared to LPS-enhanced production.
Discussion
The inhibitory effect of DEX in this in vitro
experiment varied considerably from donor to
donor. The effect of DEX on the release of TNF-
a, IL-6 and PGE2 cannot be explained by the
effect of DEX on the viability of the cells, other-
wise the same effects should have been found
for LTB4 release. Instead, no significant differ-
ences were found between LTB4 production in
the presence versus the absence of DEX. This
might indicate that corticosteroids do not inhibit
5-1ipoxygenase in MNC as they do the gene
expression of .cytokine-induced cycloxygenase 2
in monocles.
4 Furthermore, culture of MNC
with DEX, in the concentrations used in this
study, did not affect the viability of these cells as
determined by trypan blue exclusion. The fact
that the effect of DEX could be diminished or
even abolished by pre-incubation of the MNC
with RU486, a steroid receptor antagonist,
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FIG. 2. Effect of DEX on the secretion of (A) TNF- (O), (B)IL-6
(V) and (C) PGE2 (O); and the effect of DEX after preincubation
of MNC with RU486 10-8M (I-I) or 10-6M ([]). RU486 signifi-
cantly inhibits the effect of DEX in a dose dependent fashion, p
< 0.001.
strongly suggests a glucocorticoid receptor
mediated process.
Mononuclear cells play a central role in
chronic inflammation. They possess the capacity
to produce eicosanoids and cytokines which
modulate the inflammatory response.
5-7 Corti-
costeroids exert their anti-inflammatory effects
partly by inhibiting the production of inflamma-
tory mediators, through a glucocorticoid recep-
tor-mediated process. This means that the GRMechanism ofanti-inflammatory eects ofglucocorticosteroida
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FIG. 3. Scatchard plot of specifically bound 3H-dexamethasone
to MNC. MNC were incubated with O-16 nM 3H-dexamethasone
in the absence or presence of a O00-fold excess of unlabelled
RU486. Kd and Brax in the case shown are 12.8nM and 15.7
fmol/106 MNC respectively.
plays a crucial role in the anti-inflammatory
effects of corticosteroids.
Considering these findings it seems logical that
inter-individual variations in reaction to cortico-
steroids could be explained by variation in the
number of GR on the MNC or the affinity of
these receptors for DEX. No correlations were
found, however, between the IC50 of the media-
tors under investigation and the receptor number
or I. Thus, the degree of response of MNC of
healthy donors to DEX does not seem to be
determined by the characteristics of the GR, and
other factors must play a role. This finding,
however, does not exclude the possibility that
changes in GR number or affinity are important
in glucocorticoid resistance in inflammatory dis-
eases.
The MNC used in this study were isolated
from blood obtained from healthy volunteers,
who presumably have a normal response to cor-
ticosteroids. It is to be expected that comparison
of MNC obtained from patients who have proven
to be non-responders to corticosteroids, with
MNC of responders may reveal differences in GR
characteristics more clearly. Studies with MNC
isolated from blood obtained from inflammatory
bowel disease patients who respond to cortico-
steroids and patients who do not respond have
been initiated.
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